Literature DB >> 8486873

Relief of severe pulmonary hypertension after closure of a large ventricular septal defect using low dose inhaled nitric oxide.

M Berner1, M Beghetti, B Ricou, J C Rouge, R Prêtre, B Friedli.   

Abstract

A 16-month-old girl developed severe pulmonary hypertension after closure of a large ventricular septal defect. All conventional therapeutic measures failed; an attempt to add nitric oxide at a continuous low dose to the inspired gas allowed resolution of pulmonary hypertension and low cardiac output. This report documents that continuous inhalation of low dose nitric oxide is capable of selective resolution of pulmonary hypertension following cardiac surgery for a large septal defect in a child. This suggests that a transient dysfunction in the release of nitric oxide by the pulmonary endothelial cell is responsible for the vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486873     DOI: 10.1007/bf01708365

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

1.  Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J P Kinsella; S R Neish; E Shaffer; S H Abman
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

2.  Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.

Authors:  C Frostell; M D Fratacci; J C Wain; R Jones; W M Zapol
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

3.  EDRF/nitric oxide. The endogenous nitrovasodilator and a new cellular messenger.

Authors:  R A Johns
Journal:  Anesthesiology       Date:  1991-12       Impact factor: 7.892

Review 4.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

Review 5.  Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein.

Authors:  L J Ignarro
Journal:  Circ Res       Date:  1989-07       Impact factor: 17.367

6.  Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.

Authors:  L J Ignarro; G M Buga; K S Wood; R E Byrns; G Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

Review 7.  Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function.

Authors:  S Moncada; M W Radomski; R M Palmer
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

Review 8.  The discovery of nitric oxide as the endogenous nitrovasodilator.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Hypertension       Date:  1988-10       Impact factor: 10.190

9.  Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J D Roberts; D M Polaner; P Lang; W M Zapol
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

10.  Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep.

Authors:  M D Fratacci; C G Frostell; T Y Chen; J C Wain; D R Robinson; W M Zapol
Journal:  Anesthesiology       Date:  1991-12       Impact factor: 7.892

  10 in total
  7 in total

1.  Evaluation of Mapleson systems for administration of inhaled nitric oxide.

Authors:  I Kukita; K Okamoto; T Sato; Y Shibata; K Shiihara; K Kikuta
Journal:  J Anesth       Date:  1996-03       Impact factor: 2.078

2.  Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension.

Authors:  M I Turanlahti; P O Laitinen; S J Sarna; E Pesonen
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

3.  Hemodynamics and oxygenation changes induced by the discontinuation of low-dose inhalational nitric oxide in newborn infants.

Authors:  M Françoise; J B Gouyon; J C Mercier
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

4.  Guidelines for the safe administration of inhaled nitric oxide.

Authors:  O I Miller; D S Celermajer; J E Deanfield; D J Macrae
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-01       Impact factor: 5.747

5.  Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients.

Authors:  M Beghetti; W Habre; B Friedli; M Berner
Journal:  Br Heart J       Date:  1995-01

6.  Fluctuations of inspired concentrations of nitric oxide and nitrogen dioxide during mechanical ventilation.

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

Review 7.  The role of nitric oxide in cardiac surgery.

Authors:  Y Nonami
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.